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Glioblastoma multiforme (GBM) is a lethal brain cancer with a median survival 
time (MST) of approximately 15 months following treatment.  A serious challenge facing 
the development of new drugs for the treatment of GBM is that preclinical models fail to 
replicate the human GBM phenotype.  Here we report the Johns Hopkins Oncosphere 
Panel (JHOP), a panel of GBM oncosphere cell lines. These cell lines were validated by 
their ability to form tumors intracranially with histological features of human GBM and 
GBM variant tumors. 
We then completed whole exome sequencing on JHOP and found that they 
contain genetic alterations in GBM driver genes such as PTEN, TP53 and CDKN2A.  
Two JHOP cell lines were utilized in a high throughput drug screen of 466 compounds 
that were selected to represent late stage clinical development and a wide range of 
mechanisms.  Drugs that were inhibitory in both cell lines were EGFR inhibitors, NF-kB 
inhibitors and apoptosis activators.  We also examined drugs that were inhibitory in a 
single cell line.  Effective drugs in the PTEN null and NF1 wild type cell line showed a 
limited number of drug targets with EGFR inhibitors being the largest group of cytotoxic 
compounds.  However, in the PTEN mutant, NF1 null cell line, VEGFR/PDGFR 
inhibitors and dual PIK3/mTOR inhibitors were the most common effective compounds.  
Using active compounds from the single agent screen, we subjected two 
oncosphere cell lines to a drug combination matrix high throughput screen.  Synergistic 
combinations were tested in vivo and a PIK3 inhibitor paired with three different drugs 
extended survival in the JHH-520 GBM model. This data shows that the JHOP is 
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amenable to a high throughput drug screening format and that future preclinical studies 
on active compounds found in these results may deliver promising therapeutic leads.  
Advisor: Dr. Gregory J. Riggins 
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History of GBM Therapeutics and Current GBM Clinical Trials 
Malignant astrocytomas are the most common glial tumor type. Grade IV 
astrocytoma, more commonly known as Glioblastoma (GBM), is the most malignant 
glioma, and makes up 80% of the annual incidence of adult glioma in the United States.  
GBM is classified by the World Health Organization (WHO) as a diffusely infiltrative 
tumor with features including microvascular proliferation, nuclear atypia, mitosis, and 
regions of necrosis (Louis et al.). GBM can be further classified as primary or secondary 
according to common genetic mutations, which seem to separate into two distinct groups.  
Primary GBM is defined as a tumor that arises de novo with no patient history of 
tumor and makes up 90% of CNS tumors in adults.  GBM variants exist which are 
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classified by histological characteristics.  Gliosarcoma is a rare variant that shows 
histological features of both glioma and sarcoma (Evanthia Galanis et al.). GBM can also 
contain areas of different tumor types.  Primitive neuroectodermal tumor (PNET) can 
exist in a GBM, characterized by areas of multipotent embryonic cells (Perry et al.).  
Areas of oligodendroglioma, a glioma subtype composed of cells of oligodendroglial 
origins, can also be found in some GBMs(Louis et al.).  Although histological differences 
define GBM variants, there is little or no difference in patient treatment between a pure 
GBM and a GBM variant. Tumor recurrence causes the death of the almost all GBM 
patients. 
Due to limited treatment options, the median survival time for GBM patients is 14 
-18 months following diagnosis (DeAngelis).  The current standard of care for patients 
diagnosed with GBM is surgical resection followed by concomitant radiation therapy and 
oral temozolomide (Temodar® or TMZ) (Walker et al.) (Stupp et al.) Bis-
chloroethylnitrosourea (BCNU) impregnated wafers, Gliadel, have also been shown to 
extend survival in patients with recurrent and newly diagnosed disease (Stupp et al.) 
(Gallia, S. Brem, and H. Brem).  Although the Vascular Endothelial Growth Factor 
(VEGF) inhibitor Bevacizumab (Avastin®) provides clinical improvement, there is no 
clear evidence of a survival benefit with the addition of Bevacizumab (Lai et al.).   Once 
GBM patients no longer benefit from the existing therapies, treatment options are 
normally limited to experimental therapies.  Although many clinical trials have been 
attempted to generate new therapeutic options for GBM patients, few have demonstrated 
a statistically significant survival benefit.   
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 The timeline of approved therapies for GBM has had large gaps of time without 
new developments.  The first non-surgical treatment for GBM patients, radiation therapy, 
was approved in 1980.  25 years later, TMZ was approved followed by Avastin five years 
later.  Numerous clinical trials have been performed, however very few have led to 
approved therapies with a significant survival benefit.  Small molecule inhibitors have 
been tested in GBM but without great success. There are currently hundreds of small 
molecules in clinical trials for GBM, many of them within the same drug class (Table 1).  
The most common drug classes are traditional chemotherapeutic agents that have been 
successful in other cancers.  All these clinical trials were initiated based on data from pre-
















Table 1 – Small molecules that have been evaluated in clinical trials for GBM as listed on 
www.clinicaltrials.gov 
Mechanism of Action/Drug Target Investigational Agents 
Topoisomerase Inhibitors Irinotecan, Gimatecan, Topotecan, Etoposide, 
Camptothecin, Pyrazoloacridine, Karenitecin, 
Erinotecan, Astrasetecan, Acridine carboxyamide, 
Lucanthone, Edotecarin 
Platinum containing compounds Carboplatin, Cisplatin, Oxaliplatin 
Anti-angiogenesis Thalidomine, Lenalidomide 
mTOR inhibitor Sirolimus, Temsirolimus, Everolimus, AP25373, 
AZD8055, CC-223 
EGFR Inhibitors Erlotinib, Lapatinib, Gefitinib, Afatinib, AC4280, 
Dacomitinib, AEE788, ABT-414 
VEGFR/PDGFR Inhibitors Sunitinib, Sorafenib, Cediranib, Vandetanib, 
Pazopanib, Nintedanib, Vatalanib, Tandutinib, 
Cabozantinib, Axitinib, Crizotinib, PLX3397, 
Dovitinib, Crenolanib, SU5416, NVP-BGJ398, 
INC280, Tivozanib, E7050, E7080 
HDAC Inhibitors Vorinostat, Panobinostat, Romidespin, Entinostat 
Farnesyl Transferase Inhibitors Lonafarib, Tipifarnib, SCH66336 
Bcr-Abl Inhibitors Dasatinib, Imatinib, Bosutinib, Bafetinib 
Anti-angiogenesis Cilengitide, ABT-510 
Alkylating agents Cyclophosphamide, Busulfan, Melphalan 
hydrochloride, SarCNU, Fotemustine, VAL-083, 
Cloretazine, TH-302, Irofulven, Glufosfamide, 
Semustine 
Ribonucelotide reductase Inhibitor Motexafin gadolinium, gemcitabine 
PKC inhibitor Enzastaurin 
Proteasome Inhibitor Bortezomib 
SMO receptor antagonist Vismodegib, LEQ506 
Microtubule stabilizer Paclitaxel, TPI-287, Cabazitaxel, Docetaxel, 
MPC-6827, Epithilone, Ixabepilone, CYT997, 
Ortataxel 
Anthracycline Doxorubicin, RTA 744 
Protease Inhibitor Ritonavir, Lapinovir, Nelfinavir 
Gamma secretase Inhibitor RO4929097 
Selective Estrogen Receptor 
Modulator 
Tamoxifen, CC-8490 
Retinoic Acid Receptor Isotretonin 




Calcium channel blocker Carboxyamidotriazole Orotate 
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Pyruvate dehydrogenase Inhibitor Dichloroacetic acid 
TGF-β Kinase Inhibitor LY2157299 
Anti-metabolite Capecitabine, 6-thioguanine, 5-fluorouracil, 
Cladribine, Alanosine, Mercaptopurine, Ara-C 
Folate anti-metabolite Pemetrexed, Methotrexate 
Anti-malarial Hydroxychloroquine 
PIK3/mTOR Inhibitor XL765, GDC-0084 
Oxygen diffusing enhancing 
compound 
Trans sodium crocetinate 
Antiviral Valcyclovir, Valgancyclovir 
Retinoid derivative Fenretinide 
Ang1/Ang2 Inhibitor Trebananib 
Bcl2 Inhibitor Gossypol 
Alcohol dehydrogenase inhibitor Disulfiram 
AKT Inhibitor MK-2206 
NSAID Celecoxib, Vioxx 
Tetracycline antibiotic Minocycline, Incyclinide 
PBN derivative OKN-007 
Synthetic lipid Minerval 
Tropomyosin receptor kinase 
inhibitor 
AZD7451 
Tubulin polymerization Inhibitor Mebendazole, Vinorelbine 
Antimicrobial Taurolidine 
Benzodiazipine ECO-4601 
PARP Inhibitor E7016, MK-4827, ABT-888, Olaparib 
Cdk inhibitor PD 0332991 
MMP Inhibitor Prinomastat 
Stat3 Inhibitor WP1066 
DNA-PK/mTOR Inhibitor CC-115 
Wee kinase Inhibitor MK-1775 
PDE5 Inhibitor Sildenafil 









GBM Pre-clinical Models 
 In vitro and in vivo models of GBM are critical to the advancement of new drugs 
to human clinical testing.  Glioblastoma cell lines are all generated from surgical 
specimens, however they differ in their culture conditions.  GBM cell lines can be 
classified into two groups: adherent and oncosphere cell lines.  Adherent cell lines are 
grown in media containing serum and cells grow as a monolayer that is adherent to the 
cell culture flask.  Oncosphere cell lines are grown in media containing no serum and 
growth factors such as EGF and FGF.  Oncosphere cell lines grow in suspension and 
form spherical groups of cells.  Both cell types have advantages and disadvantages. 
The commonly used adherent GBM cell lines are U87-MG, LN229, and T98G, all 
of which are available for purchase from American Type Culture Collection (ATCC) 
allowing for widespread use of these lines for research purposes. As of March 2014, 
ATCC has no GBM oncosphere cell lines available for purchase, which limits the 
widespread use of these cell lines.  Oncosphere cells are seen as superior to adherent cell 
lines because within a spheroid, cells are in a three dimensional space and are exposed to 
differing amounts of oxygen, nutrients and drugs, much like an in vivo tumor (Santini and 
Rainaldi).  Methods for generation and culture of GBM oncosphere cell lines were first 
published in 2002 and were shown to have the ability to express glial and neuronal 
markers (Ignatova et al.). While the creation of GBM oncosphere cell lines was published 
less than 15 years ago, these cell lines are only recently gaining widespread use.  There 
are currently no GBM oncosphere cell lines available for purchase from the ATCC.  Both 
these adherent and oncosphere cell lines can give rise to GBM in animals, however there 
are vast differences between the resulting tumors. 
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In vivo model systems for GBM therapeutic testing are a deciding factor in 
whether a drug is moved forward to clinical trials.  Rodents with compromised immune 
systems are implanted with human GBM cell lines and tumors are allowed to grow. GBM 
tumors can be established in two locations on the rodent, subcutaneous or intracranial.  
Subcutaneous, or flank GBMs grow as a compact mass with no infiltration of 
surrounding tissue which is histologically unlike human GBM growth. Another 
disadvantage of using subcutaneous GBM models for testing of new therapeutics is they 
do not have a blood brain barrier (BBB). The ability of a compound to pass the BBB is a 
major consideration in human drug testing. Taken together, subcutaneous GBM models 
are a poor system for use in pre-clinical testing of new therapeutics.   
Intracranial implantation of GBM cells is a superior model for pre-clinical testing 
for many reasons.  First, the realistic drug delivery in intracranial models allow for 
determining if the systemically delivered drug is reaching its target at effective 
concentrations. Secondly, recent studies have shown differences between which type of 
GBM cell line used in intracranial models can dictate how closely the tumor replicates 
features of human GBM.  Intracranial GBM tumors grown using oncosphere cell lines 
show histological features of human GBM such as neovasculature, mitotic figures and 
infiltrative tumor growth (Galli et al.). When U87-MG cells are grown intracranially, 
they grow as an intact mass that does not infiltrate surrounding brain tissue.  Recent 
studies have shown that oncosphere cell lines generated from GBM variants, such as 
gliosarcomas, can replicate the histological features of these variants in vivo  (Wakimoto 
et al.).  
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Another major advantage of oncosphere cell lines is that these cell lines maintain 
the genomic profile of the original tumor better than serum-grown adherent cell lines.  
Adherent and oncosphere GBM cell lines generated from the same tumor were 
genetically compared to the original patient tumor.  Oncosphere cell lines maintained the 
original mutations, chromosomal aberrations, and transcriptional patterns present in the 
original tumors (J. Lee et al.).  Adherent cell lines were found to have de novo point 
mutations, significant increases in chromosomal numbers and vastly different 
transcriptional patterns compared to the original tumors.  Taken together, research has 
shown that GBM oncosphere cell lines are a superior in vitro and in vivo model due to 
their ability to maintain the genotype and phenotype of the original patient tumor. 
PIK3 and Ras Signaling Pathways 
The PI3K pathway is controlled in part by Receptor Tyrosine Kinases (RTKs) 
located on the cell surface which transmit intracellular growth signals.  Upon binding of a 
particular ligand to the RTK, an autophosphorylation event occurs on the intracellular 
domain of the RTK resulting in exposure of phosphotyrosine residues.  This allows for 
the binding of phosphatidylinositol 3-Kinase (PI3K) to the intracellular portion of the 
RTK through its Src Homology 2 (SH2) domain.  Activated PI3K can then phosphorylate 
phosphatidylinositol (4,5)-bisphosphate (PIP2) into phosphatidylinositol (3, 4, 5)-
trisphosphate (PIP3).  The presence of PIP3 on the plasma membrane allows inactive 
AKT to translocate to the plasma membrane where it binds PIP3 through its plexstrin 
homology (PH) domain.  This translocation is sufficient to allow for phosphorylation of 
AKT (Andjelkovic et al.).  Pyruvate dehydrogenase kinase 1 (PDK1) and other kinases 
can now phosphorylate AKT at the T308 and S473 sites, which fully activate AKT.  
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PhosphoAKT can now phosphorylate many other downstream targets, which are 
involved in the regulation of cell growth and survival.  The main negative regulator of 
AKT signaling is Phosphatase and Tensin Homologue (PTEN).  PTEN is an enzyme that 
is able to turn off AKT signaling by dephosphorylating PIP3 to create PIP2 which blocks 
the binding of AKT thereby turning off activation of AKT which blocks phosphorylation 
of downstream targets.  Downstream targets of AKT include GSK-3β, MDM2, mTOR, 
BAD and FoxO proteins (Datta et al.) (Diehl et al.) (Mayo and Donner) (Cai et al.) 
(Biggs, Cavenee, and Arden) (Brownawell et al.). The entire PIK3 pathway is shown in 
Figure 1. This pathway is crucial to cell growth and also plays a role in the ability of the 








Figure 1 – The PIK3/PTEN signaling pathway.   
This pathway is frequently mutated in GBM causing elevated phosphoAKT levels. The 
end result of this is a cell that has self-sufficiency in growth signals, is insensitive to anti-
growth signals, has limitless replicative potential and can evade apoptosis.  Red indicates 
inactive proteins and blue indicates active proteins. 
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The Ras/Raf/MAPK pathway is initiated by Receptor Tyrosine Kinases (RTKs) on the 
cell surface, in the same way as the PIK3 pathway.  The binding of ligand to the 
extracellular portion of the receptor triggers an autophosphorylation event on the 
intracellular domain.  This exposes phosphotyrosine residues that allow for binding of 
proteins such as Growth factor receptor-bound protein 2 (GRB2) through its SH2 domain.  
GRB2 is an adaptor protein with an Src homology 3 (SH3) domain, which allows for 
binding of other signaling proteins with an SH3 domain.  Son of Sevenless (SOS) binds 
to GRB2 and this binding sets up the needed components to activate Ras.  Ras is a G 
protein that is activated by binding GTP. SOS is a guanine nucleotide exchange factor 
(GEF) that binds to Ras-GDP and exchanges the GDP for GTP.  Ras-GTP is active and 
can then go on to activate other downstream proteins.  Ras-GTP is inactivated by the 
hydrolysis of GTP to GDP.  Proteins with GTPase Activating Protein (GAP) function, 
such as Neurofibromin 1 (NF1), facilitate this process.  Since NF1 is able to inactivate 
Ras-GTP, it serves as a critical negative regulator of the Ras pathway. This cycle of 
switching from active Ras-GTP to inactive Ras-GDP and back drives downstream 
signaling events.  Ras-GTP can activate Raf kinases that will phosphorylate downstream 
kinases to activate a Mitogen Activated Protein Kinase (MAPK) cascade.  The first 
protein in the MAPK cascade is MEK or MAPKK.  After MEK is phosphorylated, it will 
then phosphorylate ERK.  ERK will then phosphorylate more proteins such as RSK and 
transcription factors such as CREB.  The entire Ras pathway is shown in Figure 2.  The 
overall result of this signaling pathway on the cell is to activate cell growth pathways.  
Proteins in both the PIK3 and Ras pathways are frequently altered in GBM and this 




Figure 2 – The Ras/Raf/MAPK signaling pathway.   
This pathway is frequently overactive in GBM due to loss of NF1 which causes the cell 
to have consistent activation of growth signals and limitless replicative potential.  Red 
indicates inactive proteins and blue indicates active proteins. 
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Signaling Pathway Mutations in GBM 
High throughput analyses of the glioblastoma genome have been used to discover 
the mutations that are most likely driving tumor cell growth.  A comprehensive study of 
the glioblastoma genome was completed by extensive sequence analysis of over 20,000 
protein coding genes in 22 GBM tumor samples (Parsons et al.). Genes with alterations in 
at least two of the 22 samples were then assessed in 83 additional GBMs.  Additional 
copy number and gene expression analysis was integrated with the mutation data to form 
a list of GBM candidate cancer (CAN) genes.  These 10 GBM CAN genes were the most 
frequently mutated and were more likely to be drivers of GBM cell growth.  Another 
study completed copy number, gene expression and DNA methylation analysis on 206 
glioblastoma samples.  Of these, 91 samples also underwent mutational analysis  
(McLendon et al.).  Both these studies found similar genes to be frequently altered in 
GBM.  Many of these frequently altered genes were found to be players in the PIK3 
Pathway and the Ras pathway.   
Many different RTKs can activate the PI3K and Ras pathways.  EGFR is 
amplified in about 36% of glioma samples (Rao et al.) with a further rearrangement of the 
amplification in about a third of cases yielding an internally deleted novel protein, such 
as EGFRvIII (a.k.a delta EGFR) (Wong et al.). The EGFRvIII mutation is a large deletion 
of the kinase domain of EGFR, which creates a constitutively active form of the receptor 
in the absence of EGF binding.  Although EGFR is the most commonly mutated 
oncogene in GBM samples, other RTKs are amplified in GBM.   A survey for mutations 
in the kinase domains of 20 RTK genes in glioblastoma samples found mutations in 
Platelet Derived Growth Factor Receptor Alpha (PDGFRA) and Fibroblast Growth 
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Factor Receptor 1 (FGFR1).  Neither of the mutations was found to be activating, 
however the downstream effects of these mutations was not explored in this study (Rand 
et al.). Another study found KIT, Vascular Endothelial Growth Factor 2 (VEGFR2) and 
PDGFRA amplification in 47%, 39% and 29% of 43 primary glioblastoma samples, 
respectively (Joensuu et al.) /FGFR1 was shown to have point mutations in GBM tumor 
samples and later was it was shown that disruption of Fibroblast Growth Factor (FGF) 
signaling suppresses GBM cell growth (Loilome et al.).  Early studies showed that 
glioma cell lines express basic Fibroblast Growth Factor (bFGF) and grow in response to 
bFGF (Morrison, Yamaguchi, et al.).  Further studies showed the FGFR1 mRNA and 
protein levels are highly expressed in GBM tumor samples (Morrison, Giordano, et al.).  
Taken together, these studies indicate that many different RTKs are amplified in GBM. 
 Once the RTK binds its ligand, the next step in the PIK3 pathway is activation of 
PI 3-kinase, which contains a catalytic and regulatory subunit, p110 and p85, which are 
products of the PIK3CA and PIK3R1 genes, respectively.  The p85 domain allows 
binding of PI 3-kinase to the phosphotyrosine residues on the intracellular domain of the 
RTK and the p110 domain catalyzes the phosphorylation of PIP2 into PIP3.  Both of 
these genes were identified in the mutational analysis of the glioblastoma genome as 
drivers of GBM cell growth (Parsons et al.; McLendon et al.).  Many large mutational 
analyses have been done to find PIK3CA mutations in glioblastomas (Samuels et al.; 
Broderick et al.; Mueller et al.; Hartmann et al.; Knobbe, Trampe-Kieslich, and G. 
Reifenberger; Gallia et al.) although few of these studies were able to identify activating 
mutations.  Following PI 3-kinase activation, PIP3 becomes abundant on the plasma 
membrane and AKT can translocate and bind to PIP3.  Surprisingly, activating mutations 
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in AKT itself are very rare in gliomas, however amplification of AKT have been found in 
some GBM samples (McLendon et al.). 
 A major regulator of AKT signaling is the PTEN gene.  PTEN was first shown to 
be mutated in GBM and other cancers in 1997 (Li, Yen, et al.).  It was identified as a 
tumor suppressor gene in gliomas in 1998 (Cheney et al.).  In the same year, PTEN was 
shown to inhibit phosphoAKT and block programmed cell death by introducing wild type 
PTEN in glioma cell lines that previously lost PTEN expression (M. A. Davies et al.).  A 
similar result was found when tumors formed after glioma cell lines were introduced into 
the flank of a nude mouse (Cheney et al.).  Later studies showed that PTEN acts as a 
tumor suppressor by inducing apoptosis in normal cells that have DNA damage (Li, 
Simpson, et al.).  However, the mechanism of how PTEN blocked AKT activation had 
yet to be elucidated.  It was first shown that PTEN dephosphorylated PIP3 (Maehama and 
Dixon).  In 1999, it was discovered that PTEN’s regulation of PIP3 levels in the cell 
controls activated AKT ability to phosphorylate downstream targets (Sun et al.).  Further 
studies showed that while PTEN is a tumor suppressor gene, loss of PTEN results in 
activated AKT, an essential outcome that creates an oncogenic signal within a cell (Stiles 
et al.).  It was shown in glioma cell lines that expression of PTEN resulted in a decrease 
in phosphoAKT and re-expression of wild type PTEN increased the number of apoptotic 
cells.  This indicates that when phosphoAKT levels are low, like in a cell with wild type 
PTEN expression, glioma cells are able to undergo apoptosis.  However, if PTEN 
function is lost, then phosphoAKT levels can remain elevated and the cell will be unable 
to undergo apoptosis (M. A. Davies et al.).  The overall effect of activating mutations in 
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various RTKs, PIK3CA, and loss of PTEN expression is elevated phosphoAKT levels  
which pave the way for a normal cell to acquire oncogenic traits. 
The Ras pathway has been studied in glioblastoma, however less extensively than 
the PTEN/PIK3/AKT pathway.  The initial genes involved in the Ras pathway are HRAS, 
KRAS and NRAS.  Early studies of RAS mutations established that these mutations were 
not present in GBM cell lines and tumor samples (Bos).  Another study of Ras expression 
in malignant astrocytoma found increased levels of Ras-GTP in glioma cell lines and 
tumor samples compared to normal astrocytes, however no activating mutations were 
found in any Ras genes (Guha et al.). A later study showed that induction of 
constitutively active Ras in glioma cell lines caused the cells to undergo cell death that 
was physically distinct from apoptosis (Chi and Kiatanka). The creation of genetically 
engineered mouse models of glioblastoma found that constitutive activation of KRAS 
and AKT are required for glioblastoma formation in mice (Holland et al.).  This was the 
first study showing the importance of Ras activation in glioblastoma cell growth in an in 
vivo system. This was followed by a study that examined mutations in HRAS, KRAS, 
NRAS in 94 glioblastoma samples found two samples with mutations in NRAS (Knobbe, 
Trampe-Kieslich, and G. Reifenberger).  Recent studies found that RAS genes were 
mutated in only 2% of 91 GBM tumor samples (McLendon et al.) but these alterations 
were not drivers of GBM growth. Overall, the presence of RAS gene mutations in 
glioblastoma is very low, however Ras activation is required for gliomagenesis in vivo.  
This has been explained by the prevalence of EGFR, PDGFR and MET amplification in 
GBM that would keep Ras in an activated state. 
 16 
 
The RAF kinase gene family contains three members: ARAF, BRAF and RAF1.  
Of these genes, BRAF is most frequently mutated in human cancers (H. Davies et al.).  
BRAF mutations are found in GBM but at a low incidence.  The first mutational study of 
BRAF in glioblastoma found three samples with BRAF mutations out of 94 examined 
(Knobbe, J. Reifenberger, and G. Reifenberger).  The first assessment of copy number 
alterations in RAS/RAF genes in glioblastoma samples found that 76% contained gains in 
BRAF (Jeuken et al.) The high incidence of BRAF amplification is likely due to the 
location of the gene on chromosome 7, which is frequently amplified in GBM.  Further 
studies showed that constitutive activation of RAF1 and AKT caused formation of 
glioblastomas in vivo (Lyustikman et al.; Robinson et al.).  Taken together, these studies 
show that BRAF mutations in GBM are rare however amplifications can be found which 
would cause over activation of the Ras/Raf pathway. 
A critical regulator of the Ras/Raf pathway is the NF1 gene.  The link between 
NF1 and astrocytoma has been heavily explored due to the inherited disease 
Neurofibromatosis.  Dr. Freiderich Daniel von Recklinghausen first described this disease 
in 1882. The autosomal dominant disease is characterized by small tumors that develop 
on nervous tissue and the development of tumors of the central nervous system.  The NF1 
and NF2 gene loss were found to be the cause of Neurofibromatosis Type 1 and Type 2, 
respectively.   The NF1 gene was found early on to be frequently lost in astrocytomas (el-
Azouzi et al.) and was hypothesized to be a tumor suppressor gene.  A later study found 
NF1 to be mutated in a small number of glioblastomas  (Thiel et al.). A genetically 
engineered mouse model of glioblastoma was developed using a mutant NF1 and mutant 
TP53 (Reilly et al.) (Zhu et al.). Genomic studies revealed that NF1 is frequently lost or 
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mutated in 15-18% of glioblastomas (Parsons et al.; McLendon et al.).   The overall effect 
of amplified RTKs and loss of NF1 causes the Ras pathway to be overactive causing the 
GBM cell to have uncontrolled cell growth. 
 
Hypothesis and Research Summary 
 Our hypothesis is that glioma oncosphere cell lines are a better pre-clinical model 
than traditional adherent cell lines.  We believe that using these cell lines for testing new 
GBM therapeutics will lead to more successful clinical trials.  To test this hypothesis, we 
generated nine oncosphere cell lines and completed whole exome sequencing on them.  
This analysis revealed the genomic profile in each cell line and allowed us to determine 
the best therapeutic targets.  Two cell lines were selected for a high throughput drug 
screen of 466 drugs.  We found that certain drugs were very efficacious in both cell lines 
however a large group of drugs were effective in only a single cell line.  Top hits from 
this screen were selected for a matrix combination screen to determine what drugs have 
synergy in combination with each other.  Two cell lines underwent this matrix screen and 
data showed that the most effective combinations involved a drug that inhibits members 
of the PIK3 or Ras pathway paired with a drug that inhibits a vital cellular process.  
These combinations were tested in vivo and a significant extension of survival was found 
in three different drug combinations.  This research is the first full genomic 
characterization of a panel of glioma oncosphere cell lines and the first use of glioma 












Oncosphere Cell Line Generation 
 Patients with a suspected GBM were identified prior to their surgery at Johns 
Hopkins Hospital and patient demographics were obtained using the Electronic Patient 
Records (EPR) system through an IRB approved protocol.  Tumor tissue was collected 
from the operating room during tumor resection and was transported to the laboratory on 
ice in a sterile container.  Tissue was processed in sterile conditions.  After a PBS rinse, a 
tissue chunk was frozen for storage in the tumor bank and the remaining tissue was used 
for cell line generation.  First, the tissue was dissociated using the two scalpel method 
until it reached liquid consistency.   
The sample was further dissociated using a glass tissue douncer followed by 
passage through a 16 gauge needle using added Minimal Essential Media (MEM).  The 
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sample was then incubated at 37°C with collagenase (10mg/mL in HBSS) for 15 minutes.  
Next, the sample was passed through a pre-wetted 70 micron filter and the filter was 
washed with MEM to ensure all cells were filtered.  This liquid was then centrifuged at 
180 x g for 5 minutes to pellet the cells.  If excess red blood cells were present in the cell 
pellet, red blood cell lysis buffer (BD #555899) was added to the pellet.  The sample was 
incubated in the dark for 15 minutes at room temperature. 
Cells were then pelleted and the supernatant was removed.  The pellet was 
resuspended in 1mL of PBS with 1% fetal bovine serum (Gemini, Sacramento CA) in 
preparation for centrifugation using a sucrose gradient.  1mL of 30% sucrose was added 
to the sample and centrifuged at 3,100 x g at 4°C for 20 minutes.  Supernatant was 
removed from the pellet and discarded.  JHH-505 and JHH-520 did not undergo red 
blood cell lysis or sucrose centrifugation.  The final cell pellet was resuspended in 10mL 
of complete Neurocult media (StemCell Technology #05751, Vancouver, BC) 
supplemented with EGF (20ng/mL in PBS, Peprotech #AF-100-15 Rocky Hill, NJ), FGF-
b (10ng/mL in PBS Peprotech #100-18B) and 0.2% heparin (StemCell Technology 
#07980) and placed in a T75 cell culture flask.   
Cells were grown in a humidified incubator at 37°C with 5% CO2 and were 
monitored for oncosphere formation.  Cell culture flasks were supplemented with 1mL of 
complete Neurocult media every 48-72 hours to prevent depletion of nutrients and growth 
factors.  If oncospheres were observed, cells were passaged as described previously 
(Bakir et al.).  Cell lines were considered stable after four to seven passages and were 




Cell Culture Methods 
Br23C, JHU-0879, JHH-136, JHH-68, JHH-227, JHU-1016B, JHH-505 and JHH-
520 were created in the Riggins lab.  The cell lines with a JHH designation were 
collected using an unconsented patient protocol, so samples were de-identified upon 
collection.  Cell lines with a JHU designation were collected using a consented patient 
protocol, which allowed for collection of two vials of blood from the patient and patient 
identifiers were associated with the sample collected. HSR-GBM1 cells were a gift from 
Sara Piccirillo and Angelo Vescovi to the Riggins lab. All cell lines were grown in 
suspension in Neurocult Stem Cell media containing EGF, bFGF and heparin using 
standard incubator conditions.  
Oncosphere Cell Line Validation 
 Validation of each cell line began by doing Short Tandem Repeat profiling on 
each cell line.  A Qiagen DNeasy kit (Qiagen, Valencia, CA) was used to extract genomic 
DNA and DNA concentration was determined using a Nanodrop 2000 (Thermo, 
Pittsburgh, PA). DNA was then aliquoted at 10ng/μL and sent to the Johns Hopkins 
Microarray Core Facility for STR profiling.  The StemElite ID system (Promega, 
Madison WI) was used for STR profiling and controls included HeLa, K562 and mouse 
markers. 
 In vivo tumor formation was the second validation criteria for each cell line.  5-6 
week old female athymic nude mice (NCI, Frederick MD) were used as previously 
described (Lee et al, 2006). Mice were anesthetized using a ketamine/xylazine mixture. 
250,000 to 500,000 cells were dissociated into single cell suspension then injected into 
the striatum of two to four mice using a stereotactic frame.  Surgical wounds were closed 
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using staples.  Animal weight was monitored weekly and animals were euthanized upon 
signs of neurological defects such as rapid weight loss, hunching and difficulty with 
movement.  Brains were removed and fixed in formalin for 24-48 hours then embedded 
in paraffin, sectioned and placed on slides.  H&E staining was done on all samples and 
each slide was examined for histological features of GBM by board certified 
neuropathologists.  For GBM variant tumors, the original primary tumor slides were 
compared to the xenograft for similarities. 
Exome Capture and Next Generation Sequencing 
DNA was extracted from nine oncosphere cell lines using a Qiagen DNeasy 
Miniprep Kit.  For JHU-0879, JHH-136, JHH-68, JHH-227, JHU-1016B, JHH-505, and 
JHH-520, DNA was extracted from cells that were less than 15 passages from the 
passage number used for in vivo tumor establishment.  Br23C and HSR-GBM1 are 
frequently used for in vivo experiments so any available cells were used without regard 
for passage number.  JHU-0879 and JHU-1016B matched normal DNA was extracted 
from whole blood using a Qiagen DNeasy Blood and Tissue Kit.  The STR profile of 
each sample was determined prior to sequencing to ensure each sample was independent.  
The amount of DNA in each sample was quantified using a Nanodrop Spectrophotometer.  
Library construction was completed at Johns Hopkins Microarray Core Facility. Genomic 
DNA fragmentation was performed with the Bioruptor (Diagenode), and size selection at 
200 bp - 300 bp was carried out. The exomes of gDNA were captured using the Agilent 
SureSelect All Exon 50Mb Target Enrichment kit according to the manufacturer's 
instructions.  The exomes of gDNA were captured using the Agilent SureSelect All Exon 
50Mb Target Enrichment kit according to the manufacturer's instructions. The captured 
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DNA was sequenced on the Illumina HiSeq2000 platform according to the 
manufacturer's instructions, to generate 100-base paired-end reads. Image analysis and 
base calling were performed using Illumina’s Casava1.8.2 software 
 
Reads Mapping and Variant Identification 
Reads were mapped to the human genome (GRCh37) using the Burrows-Wheeler 
Aligner (BWA) (PMID:19451168) version 0.5.9 with q=20. The resulting SAM 
(Sequence Alignment/Map) files were converted to BAM files, and sorted with 
SAMtools (PMID:19505943 v 0.1.18). PCR and optical duplicates, and multiple reads 
likely to be derived from a single cluster on the flow-cell image, were marked with Picard 
tools (v. 1.64). Regions that could benefit from realignment were identified using the 
GATK (PMID:21478889: v 1.0.5506) Realigner Target Creator. The reads covering 
localized indels were realigned, and quality values were recalibrated using GATK. The 
GATK (v. 1.5) was also used to locate, filter and annotate variants. Somatic changes 
including point mutations and small indels were called based on comparison between 
case and control. Only missense mutations were assessed for functional impact by PhyloP, 
SIFT, Polyphen, and Mutation Taster (Schwarz et al.) [8] programs.   
Evaluation of Copy Number Alteration 
Mean exonic coverage was calculated for all exonic baits in case and control 
samples by GATK. The mean exonic coverage of each exon was subsequently 
normalized by average whole-exome coverage of the sample. Individual case vs. control 
log2 ratios were then calculated for all the exons in the data set and plotted. The presence 
of copy-number alterations was detected using a combined approach involving a set of 
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statistical Wilcoxon signed-rank tests performed on a 500,000 bp sliding windows along 
the genome.  Only genetic amplifications of greater than 10 copies are reported. 
Immunoblotting 
Oncospheres were dissociated into single cells then pelleted by centrifugation at 
300xg for 5 minutes.  Media was discarded and pellets were washed using PBS and 
centrifuged at 300xg for 5 minutes.  Following removal of PBS, an appropriate volume of 
ice cold RIPA buffer containing protease and phosphatase inhibitors was added to the 
pellet.  Following a 30 minute incubation on ice, cells were centrifuged at 14000 RPM at 
4°C for 15 minutes.  Supernatant was collected and protein levels were quantitated using 
a Pierce BCA assay kit (Thermo).  20ug of denatured protein was loaded on a 10% 
polyacrimide gel.  The gel was run at 80V for 90 minutes using MES running buffer.  
Proteins were transferred to a PVDF membrane at 30V for 90 minutes at 4°C. Membrane 
was blocked in 5% milk-TBST mixture for 60 minutes at room temperature.  Primary 
antibody incubation occurred overnight at 4°C and secondary antibody incubation was 
for 60 minutes.  Membrane proteins were visualized using Pierce Chemiluminscence kit 
(Thermo) and film capture. 
 
Quantitative High Throughput Single Agent Drug Screening 
 The Mechanism Interrogation PlatE is a collection of 466 small molecules that 
target signaling pathway components that are altered in many different cancers.  Most of 
the MIPE compounds are in various stages of preclinical testing, clinical trials or FDA 
approved.  The qHTS was completed using a 48 hour cell proliferation assay measuring 
cellular ATP content and was performed in a 1536 well microplate. High base solid 
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bottom white Grenier plates (#789173) were used throughout.  JHH-136 and JHU-1016B 
were dissociated into single cells during their log growth phase then plated at 500 and 
1000 cells per well in 5 μL of NeuroCult Media using a Multidrop liquid dispenser 
(Thermo).  Next, a Pintool dispenser (Kalypsis) was used to add 23 nL of MIPE titrated 
compounds to columns 5 to 48.  Columns 1 and 2 contained DMSO and columns 3 and 4 
contained the proteasome inhibitor bortezomib at a final concentration of 9.2 μM which 
was used as a positive control for data normalization to induce complete cell killing.  The 
remaining columns contained each drug in eleven different concentrations in order to 
obtain a dose response curve.  Plates were then incubated for 48 hours with low 
evaporation stainless steel lids in standard incubator conditions.  For cell viability 
measurements, 3 μL per well of CellTiter Glo reagent (Promega) was dispensed using a 
Bioraptor liquid dispenser (BD).  After incubation for 15 minutes at room temperature, 
the luminescence signal was measured using a ViewLux CCD-based multi-label reader 
(Perkin Elmer).  Cell growth values normalized to the DMSO only control values as a 
100% activity, and bortezomib control as 0% activity.  Curve Response Class analysis 
using algorithms developed at NGCG (Inglese et al.; Yasgar et al.) were used to fit the 
qHTS data to dose response curves and determine potency (IC50) and efficacy (% max 
response) parameters for each compound tested.  The drug screen was completed in 
duplicate for each cell line and dose response parameters obtained were averaged across 
each independent experiment.  
Single agent Hit Verification and Secondary Screening 
 BIIB021, Obatoclax, and Bardoxolone methyl were selected for verification using 
a non-qHTS format.  JHH-136, JHU-0879, HSR-GBM1, Br23C, JHH-227 and JHH-520 
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were dissociated during the log growth phase and was plated at 1000 cells per well in 178 
μL of Neurocult media into a clear bottom 96 well plate.  Following an overnight 
incubation at standard incubator conditions, 2 μL of each compound was added to 
columns 3 through 10 at the following final concentrations: 10 μM, 5 μM, 1 μM, 0.5 μM, 
0.1 μM, 0.05 μM, 0.01 μM, and 0.005 μM.  Columns 1 and 12 served as a no treatment 
control, Column 2 contained DMSO and Column 10 contained bortezomib at a final 
concentration of 2 μM. 20 μL of Alamar Blue Reagent was added to each well for a final 
well volume of 200 μL.  Plate readings were taken at 0, 24, 48 and 72 hours using a 
Perkin Elmer Wallac 1420 Multilabel Counter. For Br23C and JHH-227, plate readings 
were taken every 48 hours due to slow in vitro growth rates.  Each plate contained 6 
replicates and all values are normalized to the DMSO control.  GraphPad Prism 5 was 
used to calculate IC50 values. 
 
Matrix Combination Screens 
These methods have been described previously (Griner et al.). For each cell line 
tested, a total of 1000 cells per well in 5 µL of media was dispensed using a Multidrop 
Combi dispenser (Thermo Fisher Scientific Inc., Waltham, MA) and a small cassette into 
barcoded 1536 solid bottom white Greiner One tissue culture treated plates (catalog # 
789173-F). Standard Neurocult media supplemented with EGF, FGF and heparin was 
used (Stem Cell Technologies). For the generation of standard 11 point dose response 
curves the cells were plated, followed by the immediate pintool addition of 23 nL of 
control compound (bortezomib) and library compounds using a Kalypsys pintool. For 
pre-plated matrix plates, the cells were added directly to the plates immediately after 
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compounds were acoustically dispensed using an ATS-100 (EDC Biosystems, Fremont, 
CA).  The plates were then covered with stainless steel cell culture Kalypsys lids and 
incubated at 37˚C with 5% CO2 under 95 % humidity. For cell proliferation assays, the 
cells were incubated for 48 hours and then 3 µL of CellTiter Glo luminescent cell 
viability assay reagent (Promega) was added using a Bioraptor Flying Reagent Dispenser 
(Aurora Discovery-BD). The plates were then incubated for 15 minutes at room 
temperature. The signal was captured using a 10 second exposure with a ViewLux 
(Perkin Elmer) contacting a luminescent filter. For apoptosis assays, the cells were 
incubated at either 8 or 16 hours and then 3 µL of Caspase Glo 3/7 luminescent apoptosis 
assay reagent (Promega) was added using the same method described above. Relative 
luminescence units (RLU) for each well were normalized to the median RLUs from the 
DMSO control wells as 100% viability or 0% caspase activation, and median RLUs from 
the bortezomib control wells as 0% viability or 100% caspase activation. 
Animal Drug Efficacy Studies 
Animals were maintained using approved IUCUC protocols.  Athymic nude mice 
anesthetized with a ketamine/xylazine mixture and were implanted with 500,000 Br23C 
cells intracranially using a sterotatic frame. Surgical incisions were sealed with staples.   
Seven days post implantation, animals were randomized then divided into three groups of 
five mice.  Group 1 and 2 were treated Monday through Friday by oral gavage with either 
75mg/kg of BIIB021 or 25mg/kg of Bardoxolone methyl.  Bardoxolone methyl animals 
were treated with 15mg/kg later in the experiment due to toxicity.  Group 3 control 
animals received vehicle (1:1:8 cremaphor EL: DMSO: PBS) by oral gavage.   
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For drug combination studies, 500,000 JHH-520 cells were implanted.  Animals 
were randomized then separated two groups of five mice and two groups of four mice.  
Treatment began seven days post-implantation.  Two groups of animals were treated 
Monday through Friday by oral gavage with 75mg/kg of GDC-0941 plus 75mg/kg of 
BIIB021 or 75mg/kg of GDC-0941 plus 10mg/kg of PD325901.  One group of animals 
received GDC-0941 as in the other treatment groups plus 75μg/kg of Marizomib 
intravenously twice a week.  One group of control animals received daily gavage of 
vehicle (0.5% CMC/0.2% Tween80 in water).  All animals were weighed thrice weekly 
for the duration of the experiment. Animals were sacrificed upon signs of intracranial 










 Each GBM oncosphere cell line was derived from a patient tumor with a final 
diagnosis of a GBM or a GBM variant.  The patient demographic, tumor type and 
location are listed in Table 2.  The HSR-GBM1, also known as 20913, was the only cell 
line examined that was not generated by our lab.  This cell line was a gift from Angelo 
Vescovi and was derived from a primary GBM (Galli et al.).  The Br23C cell line was 
derived from a primary GBM and was first implanted as a xenograft into nude mice.  
This xenograft, named Br23X, was then used to derive the Br23C cell line. 
 All other cell lines were generated directly from patient tumors.  The JHH-136, 
JHH-227, JHU-1016B, and JHH-520 cell lines were derived from primary GBM tumors.  
 29 
 
These patients had received no previous therapy.  The remaining cell lines were derived 
from rare GBM variant tumors. The JHH-68 cell line was derived from a recurrent 
glioblastoma that had transformed to a gliosarcoma following radiation and 
chemotherapy.  The JHU-0879 cell line was derived from a primary GBM with primitive 
neuroectodermal tumor (PNET) features.  The JHH-505 cell line was derived from a 
primary GBM with an oligodendrogliomal component.  Neither the JHU-0879 or JHH-























Table 2.  Patient Demographics 
Cell Line Gender Diagnosis Location Prior Therapy Survival* 
(Months) 
HSR-GBM1 M GBM Unknown Unknown Unknown 
Br23C F GBM Unknown None 0 
















JHH-136 M GBM Right Frontal 
Lobe 
None 17 
JHH-227 M GBM Right 
Periatrial 
Lobe 
None Lost to follow-
up 6 months 
after surgery 









None Lost to follow-
up 5 months 
after surgery 
JHH-520 F GBM Right Frontal 
Lobe 
None Lost to follow-
up 1 month 
after surgery 













Cell line independence 
 The first step to ensure that each cell line was distinct and independent was to 
complete Short Tandem Repeat (STR) profiling on each line.  STR profiling is based on 
the number of repeats at 10 sites within the genome and is critical to determine the 
signature for each cell line.  Two non-glioma cell lines, HeLa and K562, were included as 
controls.  The 20 markers within each STR profile of each cell line were compared to all 
other cell lines.  Overlap of 80% or more between two cell lines was considered evidence 
that these cell lines were not unique.  Overall, none of the cell lines showed significant 
overlap with each other and are therefore independent cell lines as shown in Table 3. 
















































520 HeLa K562 
HSR-
GBM1 20 5 6 6 7 4 5 4 6   
Br23C 5 20 8 6 3 5 5 6 3   
JHU- 
0879 6 8 20 5 2 5 5 5 8 6 7 
JHH-68 6 6 5 20 8 9 10 5 5 7 8 
JHH-
136 7 3 2 8 20 8 11 7 7 5 8 
JHH-
227 4 5 5 9 8 20 9 4 4 4 8 
JHU- 
1016B 5 5 5 10 11 9 20 9 7 5 7 
JHH-
505 4 6 5 5 7 4 9 20 9 6 7 
JHH-
520 6 3 8 5 7 4 7 9 20 6 6 
HeLa   6 7 5 4 5 6 6 20 8 













In vivo tumor formation 
 The major criteria necessary for these cell lines to be useful for therapeutic testing 
was their ability to form tumors in vivo.  Immunocompromised mice were injected 
intracranially with cells and each mouse was monitored for weight loss and signs of 
neurological defects.  Upon death of the animal, the brain was extracted and preserved in 
formalin.  Tissue was then cut and fixed on slides and H&E staining was done.  Presence 
or absence of GBM histological features was assessed by a neuropathologist.  Samples 
derived from GBM variants were compared to the primary tumor to determine if GBM 
variant features were present in the xenograft.   
 The in vivo tumor formation abilities of HSR-GBM1 and Br23C cell lines have 
been published previously (Galli et al.; Siu et al.; Bai et al.) (Joshi et al.).  Of the 
remaining cell lines, all formed tumors in vivo except for JHH-68.  A single animal died 
676 days following implantation, but the brain was negative for tumor.  All cell lines 
showed invasion along white matter tracts however JHU-0879 was the only cell line to 
form a compact mass with minimal invasion (Figure 3A-C).  All cell lines showed 
histological features that define GBM such as mitotic figures (Figure 3D), areas of 
necrosis (Figure 3E) and vascular proliferation (Figure 3F).  The level of invasion within 
the cell lines examined was greater than previous reports in other animal models (Bakir et 
al.; Di Tomaso et al.).  Additional histological features of GBM were also present such as 
invasion (Figure 3G), satellitosis (Figure 3H) and subpial tumor spread (Figure 3I).  The 
cell line establishment criteria are listed in Table 4. 
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Three of the cell lines were derived from variants of GBM containing unusual 
histologic features.   JHH-68, a gliosarcoma, was unable to be analyzed due to the 
inability of the cell line to form tumors when implanted intracrainally. JHH-505 was 
isolated from a GBM with an oligodendroglioma component (GBM-O).  In addition to 
hypercellularity and neovascularization common in GBM (Figure 4A), this primary 
tumor contained many small, round, regular cells with surrounding clear halos indicative 
of oligodendroglial differentiation (Figure 4B).  The JHH-505 xenograft tumor retained 
features of a mixed GBM, with a dominant astrocytic component (Figure 4C) but also 
numerous scattered oligodendroglial cells that were prominent in some areas (Figure 4D).  
JHU-0879 was derived from a GBM with PNET features.  The primary tumor contained 
areas of densely packed cells with scant cytoplasm and prominent nucleoli (Figure 4E).  
The xenograft contained these features as well but the nucleoli were more prominent in 
the xenograft than in the primary tumor (Figure 4F).  Throughout both tumors were an 
abundance of mitotic and apoptotic cells.  This data further validates the notion that 
oncosphere cell lines often recapitulate the histopathological features of the original 
















Table 4. Cell line establishment criteria.  
Cell Line STR 
Profiling 
In vivo tumor formation # of cells injected/ 
Average survival (Days) 
HSR-GBM1 + + 4/4 5x105/58 
Br23C + + 10/10 5x105/48 
JHU-0879 + + 1/3 5x105/87a 
JHH-68 + + 0/3 2.5x105/676a 
JHH-136 + + 3/3 6x105/161 
JHH-227 + + 3/3 2x105/71 
JHU-1016B + + 4/4 2.5x105/194 
JHH-505 + + 3/3 5x105/193 
JHH-520 + + 2/2 5x105/84 
STR: Short Tandem Repeat 





























Figure 3.  H&E stains of orthotopic tumors formed in athymic mice.  
A, Only one of the 13 lines evaluated in vivo demonstrates compact, non-invasive growth 
patterns. B, The majority of lines showed diffuse invasion of normal parenchyma.   
C, D, E, F hallmark features of glioblastoma were identified including increased mitotic 
activity, necrosis, and vascular proliferation.  G, H, I Other histologic features specific to 
invasive gliomas, including spread through white matter tracts, neuronal satellitosis, and 
subpial tumor spread.  Original magnification for panels A and B was 25x; for G and I, 
50x; for C and E, 100x; and for D, F, and H, 200x.  
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Figure 4.  H&E stains of primary tumor tissue and orthotopic tumor from the GBM 
variant cell lines showing specific features of each variant.   
A, B JHH-505 primary tumor has features of a GBM such as vascular proliferation and 
dense cellular areas and also areas of round, regular oligodendroglial cells.   
C, D JHH-505 xenograft tumor has characteristics consistent with GBM-O. 
E, F The JHU-0879 primary tumor and xenograft has areas consistent with PNET with 
hypercellularity containing cells with scant cytoplasm and prominent nucleoli. Arrows 





Each Oncosphere Cell Line has a Distinct Mutation Profile 
Each oncosphere cell line was derived from a different patient tumor therefore, 
we explored deleterious point mutations and copy number alterations within each cell line.  
We began with the previously reported top glioblastoma candidate cancer (CAN) genes 
because these genes contain mutations that are drivers of glioblastoma cell growth 
(Parsons et al.).  Table 5 shows the mutations present in all 10 CAN genes plus one 
additional oncogene, c-MYC.  We explored additional oncogenes and tumor suppressor 
genes implicated as drivers in other cancer types but found very few alterations (Table 6).  
Presence or absence of PTEN and NF1 protein was verified by Western blot (Figure 5A 
and B).  
Br23C, also called 060919, is slow growing in vitro but is notable due to its in 
vivo MST of 35 days (data not shown) and formation of brainstem tumors in rats when 
implanted into the pontine tegmentum (Siu et al.). An early xenograft from this tumor 
(Br23X) was sequenced previously (Parsons et al.). We compared the point mutations 
found in Br23X to the point mutations found in Br23C at passage 35 in order to estimate 
the amount of genetic drift that occurred over time. Br23X contained 32 missense 
mutations, found in the previous genomic assessment. Of these 32 mutations, 12 of them 
are identical to mutations found in Br23C (Table 8).  The additional 22 missense 
mutations present in Br23X that were not found in Br23C could be due to differences in 
normalized controls, genome build differences or other differences in sequencing analysis.  
  The CAN gene mutations present in Br23C are a homozygous deletion of PTEN, 
a large focal gain of c-MYC, and homozygous point mutations in NF1, TP53 and RB1 
paired with a heterozygous deletion of RB1.  The NF1 and TP53 point mutations in 
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Br23C are identical to the point mutations found in Br23X.  The NF1 mutation is located 
at a donor splice site and is predicted to cause an increase in the inclusion of this exon.  
The loss of PTEN protein and presence of small amounts of NF1 protein was consistent 
with the genomic data (Figure 5A and B).  The focal gain in c-MYC and the RB1 
mutation was not detected in Br23X. The RB1 point mutation causes a premature stop 
codon, which results in the loss of 91 amino acids at the C terminus.  The lost region 
contains the nuclear localization signal, critical phosphorylation sites and functional 
domains required for RB1 interactions with E4F1.  This mutation is also predicted to 
cause nonsense mediated mRNA decay of RB1 that would be highly deleterious since the 
second copy of RB1 is deleted. This is a classic LOH event that occurred sometime 
between the xenograft acquisition and passage 35 of Br23C. This data shows that genetic 
drift does occur over time in oncosphere cell lines. The genomic profile of this cell line is 
most consistent with Mesenchymal GBM due to the RB1 and TP53 mutations. 
HSR-GBM1 is fast growing in vitro and has an in vivo MST of 73 days (data not 
shown).  This cell line contains a large focal gain of EGFR and deleterious point 
mutations in CDKN2A, TP53, NF1 and PIK3R1.  Interestingly, these point mutations in 
HSR-GBM1 are heterozygous with no loss of the normal allele so the effect of these 
mutations on overall cell function would be minimal.  PTEN protein presence was 
consistent with the genomic data, however no NF1 protein was detected which is 
contradictory to the sequencing data (Figure 5A and B).  HSR-GBM1 closely meets the 
criteria for Mesenchymal GBM due to the presence of NF1 and TP53 mutations, however 
presence of a wild type PTEN and EGFR amplification were conflicting with the 
Mesenchymal subtype.  This mixed genomic signature maybe due to early contamination 
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of this cell line with other GBM oncosphere cell lines.  Further gene expression studies 
should be done to determine the GBM subtype of this cell line. 
JHU-0879 was derived from a GBM with primitive neuroectodermal tumor 
(PNET) features and is fast growing in vitro. The in vivo tumor formation of this cell line 
has not been verified. JHU-0879 contains a heterozygous deletion of PTEN and 
homozygous point mutations in PTEN and RB1. The PTEN mutation is in the 
phosphatase tensin domain at a highly conserved residue and is predicted to cause an 
additional splice site which could result in loss of downstream exons. This mutation 
paired with the loss of one copy of PTEN is a classic LOH event however PTEN protein 
is present despite the mutation (Figure 5A). The RB1 mutation results in a premature stop 
codon that eliminates the last 251 amino acids.  This lost region contains the nuclear 
localization signal and many of the functional sites and domains of RB1.  NF1 protein is 
present in the cell line (Figure 5B).  Interestingly, JHU-0879 also has a large focal gain of 
c-Myc, which is common in GBM with PNET features (Perry et al.).  The amplification 
of c-Myc is an indicator that our oncosphere cell line is able to retain genomic mutations 
common in the primary tumor tissue. 
JHH-68 is slow growing cell line that was derived from a gliosarcoma and 
contains a homozygous deletion of CDKN2A and PTEN.   JHH-68 also contains a point 
mutation in TP53 at a highly conserved residue in the DNA binding domain. It is 
predicted to cause a novel alternative splice site which could result in a loss of 
downstream functional sites and domains.  No PTEN protein is detectable in this cell line, 
however NF1 is intact (Figure 5A and B) which is consistent with the sequencing results.  
The in vivo tumor establishment of this cell line has not been determined.   Gliosarcomas 
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are a rare tumor type which have a genomic profile similar to GBMs (Actor et al.) so our 
data correlates well with previous studies. Interestingly, this cell line is the only one that 
does not form tumors when implanted in vivo so this profile may be useful in determining 
the necessary mutations needed to form tumors. 
JHH-136 is a fast growing cell line that was derived from a GBM. The in vivo 
MST of JHH-136 is 161 days (data not shown).  This cell line only contains alterations in 
two CAN genes: a homozygous deletion of CDKN2A and PTEN.  Consistent with the 
sequencing results, there is no detectable PTEN protein in this cell line, however NF1 
protein is present (Figure 5A and B). Due to the lack of alterations in CAN genes such as 
NF1 or TP53, this cell line was unable to be classified as a GBM subtype. 
JHH-227 is slow growing cell line that was derived from a GBM with an in vivo 
MST of 73 days. This cell line contains a large focal gain of EGFR, a homozygous 
deletion of CDKN2A and an LOH event in PTEN. The PTEN mutation in JHH-227 
results in alterations of the last 25 amino acids of PTEN where many phosphorylation 
sites and the PDZ domain are located. This mutation also results in the loss of the original 
stop codon and the addition of 10 amino acids on to the C terminus of PTEN.  The 
functional impact this new mutation would have on PTEN is unknown but it is possible 
that PTEN may have increased activity due to the loss of the phosphorylation sites on the 
C terminus, which are critical to keeping PTEN in an inactive state.  No PTEN protein 
was detectable in this cell line, however this may be due to the antibody being unable to 
bind to the mutated C terminus (Figure 5A).  NF1 protein is present which is consistent 
with the sequencing data (Figure 5B).  JHH-227 closely meets the criteria for Classical 
GBM due to the presence of an EGFR amplification and loss of PTEN. 
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 JHU-1016B was derived from a GBM and grows fast in vitro.  In vivo, the MST 
for this cell line is 194 days.  This fast growing cell line contains a homozygous deletion 
of CDKN2A, an LOH event for PTEN, and a heterozygous mutation in NF1.  The PTEN 
mutation in this cell line, C124W, is in the phosphatase tensin domain at a site, which is 
critical to PTEN function.  In the early studies attempting to determine PTEN function, a 
dominant negative mutant with a C124S mutation was widely used due to its total loss of 
phosphatase activity (Tamura). The C124 site has also been shown to be oxidized by 
reactive oxygen species to form a disulfide bond with Cys71 to keep PTEN in an inactive 
conformation (S.-R. Lee et al.). This function would be lost as well since the new amino 
acid at this position is a tryptophan, which cannot be oxidized. However, all other 
domains of PTEN are normal so certain PTEN functions may be unaffected by this 
mutation.  The heterozygous deletion of the second copy of PTEN leaves only the 
C124W PTEN to be active in JHU-1016B. The point mutation in NF1 should have 
minimal effect on cell function due to the presence of a wild type NF1.  PTEN protein 
and NF1 protein are detectable in this cell line despite the mutations in both genes 
(Figure 5A and 1B).  This data is consistent with the sequencing results.  JHU-1016B 
meets the criteria for Mesenchymal GBM due to the presence of an NF1 mutation and a 
no loss of PTEN. 
 JHH-505 was derived from a GBM with an oliogodendroglioma component 
(GBM-O) and is a slow growing cell line in vitro.  This is a rare and newly designated 
GBM subtype and this cell line forms tumors with histological characteristics of GBM-O. 
Examination of CAN gene alterations revealed only a homozygous deletion of CDKN2A. 
Some CAN genes had low level amplifications or heterozygous deletions but nothing 
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predicted to greatly affect cell function.  Overall, this cell line contains numerous small 
copy number variation events on all chromosomes.  We were unable to determine if 
PTEN or NF1 protein was present due to slow growth of this cell line.  Further analysis 
must be done to determine the full extent of chromosomal loss and gains in JHH-505. 
 JHH-520 is a fast growing cell line derived from a GBM.  The CAN gene 
mutations present in this cell line are a homozygous point mutation in TP53 and 
homozygous deletion of CDKN2A and NF1.  The point mutation in TP53 is in the DNA 
binding domain. Another point mutation at this site has been previously reported in 
pancreatic adenocarcinoma of a patient with Li-Fraumeni syndrome (Lefrou et al.) .  The 
H179Y mutation in the Li-Fraumeni patient was predicted to cause a complete loss of 
p53 function due to the loss of stability in the DNA binding loop.  Although the JHH-520 
p53 mutation is not the same amino acid change as the Li-Fraumeni mutation, the effect 
on protein function could be similar since a positively charged Histidine is altered to a 
negatively charged Aspartic acid. No PTEN protein was detectable in this cell line which 
was surprising due to the sequencing data showing no alteration in PTEN (Figure 5A).  
PTEN could be inactivated due to methylation changes or other mechanisms. No NF1 
protein was present which is consistent with the sequencing data (Figure 5B).   
We also compared our data to previous GBM sequencing efforts that utilized 
primary tissue. Overall, our genetic alteration frequencies are similar to previous studies 
with the biggest differences in the NF1 and EGFR (Table 9). Finally, we examined the 
effect these alterations may have on individual signaling pathways.  The pathways shown 
to be critical for GBM cell growth are the RB1, TP53, RAS, and the PI3K pathway 
(Parsons et al.; McLendon et al.).  For this analysis, we excluded alterations that occurred 
 44 
 
with a wild type copy present as the effect on pathway function was predicted to be 
minimal in these cases.  In the cases where the protein expression was contradictory to 
the sequencing data, the protein absence overruled the sequencing data.  JHH-505 was 
excluded from this analysis due to the lack of protein expression data.  Table 7 shows all 
the alterations that involved homozygous deletions, amplifications, and heterozygous 
mutations paired with heterozygous deletions or loss of protein expression regardless of 
genomic information.  PIK3 pathway alteration paired with RB1 pathway alteration was 
the most common combination. Taken together, this data shows that our oncosphere cell 
line panel contains GBM and rare GBM subtypes and that each cell line has a diverse 
genetic alteration profile.  This information paired with the ability of many of these cell 
line to form tumors intracranially makes them a superior preclinical model for testing of 




















Table 5. Oncosphere Cell Line CAN gene alterations 
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Table 6. Oncosphere and Tumor Suppressor Genes Examined 
 


























































Figure 5 - Verification of sequencing data by Western blot 
A. PTEN protein in eight oncosphere cell lines 
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Table 8. Genetic Alterations present in Br23C and Br23X 
 

















































*Wilson et al, 2014 
CDKN2A 50% 52% 66% 
TP53 40% 35% 44% 
EGFR 37% 45% 22% 
PTEN 30% 36% 66% 
NF1 15% 18% 44% 
CDK4 14% 18% 0% 
RB1 12% 11% 22% 
IDH1 11% ND 0% 
PIK3CA 10% 15%* 0% 
PIK3R1 8% 15%* 11% 
+ Only heterozygous and homozygous point mutations, homozygous deletions and amplifications greater 
than 12 copies were counted. 
^ Only heterozygous and homozygous point mutations, homozygous deletions and amplifications greater 
than 5.65 copies were counted. 
*Only heterozygous and homozygous point mutations, homozygous deletions, and amplifications greater 












Oncosphere cell lines show differential susceptibility to drug classes 
 We completed a quantitative high throughput drug screen using two GBM 
oncosphere cell lines.  JHH-136 and JHU-1016B were selected due to their similar 
growth rates in vitro (data not shown).  Both cell lines have a homozygous deletion of 
CDKN2A, which should result in uncontrolled cell division.  The genomic profile differs 
between the cell lines in their PTEN and NF1 alterations.  JHH-136 has a total loss of 
PTEN protein due to a homozygous deletion and a wild type NF1 protein is present. 
JHU-1016B contains a phosphatase dead mutant PTEN protein and the NF1 protein is 
absent.  This should result in both cell lines having constitutive PIK3 signaling however 
the non-phosphatase activity of PTEN should be normal in JHU-1016B. The loss of NF1 
in JHU-1016B should cause overactive signaling through the Ras pathway, while JHH-
136 has normal Ras signaling. Additionally, both cell lines have a low level amplification 
of EGFR with three or four copies total.  
Both cell lines were screened using the National Center for Advancing 
Therapeutics (NCATS) MIPE Oncology Collection 3.0, a 466 compound library 
containing compounds that are in various pre-clinical and clinical development, or have 
already been FDA approved.  The strength of the MIPE Oncology Collection is the 
redundancy of drug classes within the library.  For each drug target or mechanism of 
action, there are at least two different drugs in the MIPE within that class.  Assays were 
done using 500 and 1000 cells per well and all compounds were tested in a 11-point dose 
responses. Active compounds were assessed as described previously, by first examining 
the % viability at each concentration tested (Mathews et al.).  The % viability represents 
the percentage of live cells at all tested concentrations normalized to DMSO controls.  
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The maximum response, which is the % viability at the maximum concentration of 
compound tested, is a measure of the cytotoxic effect of a compound. 
The correlation of the maximum responses for each compound on JHH-136 and 
JHU-1016B shows a strong positive correlation (R2 = 0.80 and 0.85), which indicates that 
the number of cells used does not greatly affect the results of the screen and that the 
overall cytotoxic effect of the compounds is similar in both cell lines (Figure 7A and 2B).  
A hierarchical clustering of all maximum response values for each compound tested is 
show in Figure 7C. Comparison of the group means for the maximum response values for 
both cell lines using a two-tailed t-test shows minimal differences between JHH-136 and 
JHU-1016B (Figure 7D).  The selection of cytotoxic compounds was based on a 
maximum response less than 30%, meaning that 70% of cells were killed at the 
maximum concentration tested. Next, all drugs were sorted using the Curve Response 
Class (CRC) classification, as previously described (Inglese et al.).  Any compound with 
a CRC value of -1.1, -1.2, - 2.1 and -2.2 were considered high quality hits as these CRC 
values indicates a dose response with a minimum of 80% efficacy and an r2 value of 
greater than 0.9.  Any compounds with an alternative CRC value were considered 
inactive or inconclusive.  There was no significant difference in the number of 
compounds within each CRC between JHH-136 and JHU-1016B (Figure 7E). 
There were 52 compounds that were actives that in both JHH-136 and JHU-
1016B using the maximum response criteria explained above (Table 10).  Overall, the 
maximum response values for JHH-136 hits and JHU-1016B hits had similar group 
means (Figure 8A). Comparison of matched maximum response rates for each drug in 
both cell lines shows that overall most drugs have similar efficacy in both cell lines 
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(Figure 8B). Drug targets that were overrepresented in the list of actives by maximum 
response, in both cell lines, were EGFR inhibitors, NF-κB inhibitors, epigenetic 
modulators and apoptosis pathway inhibitors.  EGFR inhibitors overall were more 
effective and had lower IC50 values in JHH-136 than JHU-1016B (Figure 8C and D). 
JHH-136 has only increased PIK3 signaling so in this cell line EGFR inhibition may be 
more effective.   NF-κB inhibitors showed similar dose response curves and therefore 
similar IC50 values in both cell lines (Figure 8E and F).  Apoptosis activators showed a 
pattern of dose response in JHH-136 that indicates that this cell line is more resistant to 
cell killing by this mechanism than JHU-1016B (Figure 8G and H).  This suggests that 
cell lines with less over active signaling pathways are more difficult to induce apoptosis 
in.  Overall, this data shows that the mutational profile of a tumor can have determine the 
efficacy of some classes of drug inhibitors.   
Next, we examined hits specific to either JHH-136 or JHU-1016B.  There were 20 
hits that were selective for JHH-136 based on the maximum response being smaller in 
JHH-136 and larger than 30% activity (Figure 9A).  A total of 16 different drug 
mechanisms of action were represented in the JHH-136 specific hits with EGFR as the 
most common target (Table 11).  Effective compounds in this class were Dacomitinib, 
Afatinib, Pelitinib, Lapatinib and AEE-788.  Pelitinib is shown as a representative drug 
from this class with a very different dose response curve for JHH-136 and JHU-1016B 
(Figure 9B). Cladribine, an adenosine deaminase inhibitor, was found to have the same 
IC50 value in both cell lines. However, the JHH-136 curve is shifted downwards killing 
almost 100% of cells at concentrations greater than the IC50 value.  Only 33% of cells are 
killed at concentrations above the IC50 in JHU-1016B (Figure 9C).  The remaining JHH-
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136 specific hits have varied mechanisms of actions however only one drug within each 
class was a hit.  This data suggests that in a cell line with increased PIK3 signaling and 
normal Ras signaling, very few drug classes can slow cell growth. 
 JHU-1016B had 36 hits that were specific to that cell line (Figure 9A).  A total of 
23 different drug targets or mechanisms of action were represented in this list of actives 
(Table 12).  The most overrepresented drug targets for JHU-1016B were VEGFR 
inhibitors. Hits in this class include Foretinib, Cediranib, Regorafenib, and Sorafenib.  
Regorafenib, and Sorafenib have very similar chemical structures and each one mainly 
inhibits VEGFR along with additional activity against PDGFR and Raf kinases.  The 
dose response for Regorafenib is shown as a representative of the group (Figure 9D). 
Regorafenib is a fairly weak cytotoxic compound for both cell lines, but is able to inhibit 
less than 30% of cell growth in JHU-1016B but not in JHH-136 at the maximum dose 
tested.  This data shows that inhibition of VEGFR is more effective at high 
concentrations in cell lines with increased PIK3 and Ras signaling. 
Other drug targets that were overrepresented in the JHU-1016B selective hits.  
Dual PIK3/mTOR inhibitors were GDC-0980, GSK-2126458, and PF-0521384.  GDC-
0980 is shown as a representative of the trend of dual PIK3/mTOR inhibitors (Figure 9E).  
For JHU-1016B, GDC-0980 is more effective at higher concentrations than in JHH-136.  
Interestingly, GSK-2126458 was very effective at low concentrations in JHU-1016B 
while in JHH-136 only the highest concentrations tested were effective (Figure 9F).  
Inhibitors specific for PIK3 or mTOR, such as GDC-0941 and Torin-2 showed a dose 
response similar to GDC-0980.  Another common drug target was Cdk or Chk inhibitors 
which block the ability of cells to enter mitosis.  AT-7519 is shown as a representative of 
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this class of drugs (Figure 9G).  High concentrations of this drug are effective in JHU-
1016B but not in JHH-136.  This data shows that these classes of drugs are effective at 
low concentrations in cells with a similar mutation profile to JHU-1016B.  Taken 
together, this data shows that minimal genomic differences in cell lines can result in 
differing drug efficacy.  
 
Figure 7 (next page). Results from quantitative high throughput screen 
A. Correlation plot of maximum response between JHH-136 and JHU-1016B with 
500 cells per well (r2 = 0.85) normalized to DMSO only control.   
B. Correlation plot of maximum response between JHH-136 and JHU-1016B with 
1000 cells per well (r2 = 0.87) normalized to DMSO only control. 
C. Hierarchical clustering with Euclidean distance of maximum response in JHH-
136 and JHU-1016B.  Green represents an increase in maximum response, red 
represents a decrease and black represents no change in viability. 
D. Maximum response values for all drugs tested in JHH-136 compared to JHU-
1016B.  The group means are marked with a red line.  The means are not 
statistically significant as determined by a two-tailed t-test. 
E. Curve response class (CRC) distribution for all compounds tested.  CRC classes -
1.1, -1.2, -2.1, and -2.2 were considered active.  CRC classes -1.3, -1.4, -2.3, -2.4 










Figure 8 (next page) - Figure 3. Dose responses from pan-actives 
A. Maximum response values for 52 actives in both JHH-136 and JHU-1016B.  The 
group means are not significant as determined by a student’s unpaired t-test. 
B. Maximum response values for the 52 actives for both cell lines were matched.  
The red dots are the maximum response of a compound in JHH-136 and the blue 
dot is the maximum response of the same compound in JHU-1016B as shown by 
the connecting line. The differences are not significant as determined by two way 
ANOVA analysis. 
C. Dose response curves of AV-412, NGCG182713, WZ-4002, CUDC-101 and 
Vandetanib in JHH-136. 
D. Dose response curves of AV-412, NGCG182713, WZ-4002, CUDC-101 and 
Vandetanib in JHU-1016B. 
E. Dose response curves of CDDO-Me, Withaferin A, NGCG161703-2, and IMD-
0354 in JHH-136. 
F. Dose response curves of CDDO-Me, Withaferin A, NGCG161703-2, and IMD-
0354 in JHH-1016B. 
G. Dose response curves for Gossypol, Navitoclax, Obatoclax, TW-37, PAC1 and 
YM155 in JHH-136 
H. Dose response curves for Gossypol, Navitoclax, Obatoclax, TW-37, PAC1 and 
















































Table 10. Drug Hits for both JHH-136 and JHU-1016B 
Drug Mechanism of Action Compound Names 
EFGR inhibitors AV-412, Canertinib, WZ-4002, CUDC-101, Vandetanib^ 
NF-κB/IKK-beta inhibitors Bardoxolone Methyl, Withaferin A, NCGC00161703-02, 
IMD-0354 
Apoptosis Activators Navitoclax, Obatoclax, Gossypol, PAC-1, TW-37, 
YM155 
Epigenetic Modulators Panobinostat, BIX-01294, Belinostat, Mocetinostat 
Bcr-Abl inhibitor Nilotinib^, Ponatinib^ 
JNK inhibitors BI-78D3, SR-3306 
PI3K inhibitors Wortmannin, BAG956, CAY10626 
BMPR/ALK inhibitors LDN-193189, TAE684 
JAK1/2 inhibitors Lestaurtinib, Degrasyn 
Chk1/Cdc25 inhibitor AZD7762, NSC 663284 
HSP90 inhibitor BIIB021 
FGFR inhibitors Dovitinib 
PKC inhibitor Chelerythrine chloride 
IDO inhibitor CAY10581 
cPEPCK inhibitor NCGC00263130-01 
Proteasome inhibitor MLN-2238 
Antibacterial/Anticoccidal Salinomycin 
Seletive Estrogen Receptor Modulator Tamoxifen^ 
ERK inhibitor NCGC00242487-01 
Vitamin A acid analogue Retinoic acid p-hydroxyanilide 
PAR1 Receptor Agonist SCH-79797 
VEGFR inhibitor Nintedanib 
TAK1 inhibitor NCGC00253463-01 
Glucocorticoid Receptor Agonist Cortivazol^ 
Plk inhibitor BI-2536 
DNA-PK inhibitor Nu7441 
Substance P agonist Aprepitant^ 
Arteminisin analogue Diartallox 
Inducible T Cell Kinase inhibitor NCGC00188382-02 
Casein Kinase Inhibitor Silmitasertib 
^ drug is FDA approved 
 
 
Figure 9 (below) - Active compounds selective for either JHH-136 or JHU-1016B 
A. Venn diagram showing the number of actives in oncosphere cell line. 
B. Dose response curves for Pelitinib, an EGFR inhibitor. 
C. Dose response curves for Cladribine, an adenosine deaminase inhibitor. 
D. Dose response curves Regorafenib, a VEGFR/PDGFR inhibitor. 
E. Dose response curves for GDC-0980, a dual PIK3/mTOR inhibitor. 
F. Dose response curves for GSK-2126458, a dual PIK3/mTOR inhibitor. 













Table 11. JHH-136 Specific Hits 
 
Drug Mechanism of Action Compound Names 
EGFR inhibitors Dacomitinib, Afatinib,^ Pelitinib, Lapatinib^, AEE-788 
Adenosine Deaminase inhibitor Cladribine^ 
NF-κB inhibitor PS1145 
Ribonucleotide Reductase inhibitor Gemcitabine^ 
AKT inhibitor MK-2206 
PI3K inhibitor CAY10626 
mTOR inhibitor Everolimus^ 
Pan-tyrosine kinase inhibitor PD-166285 
Flt3/Pim inhibitor SGI-1776 
CXCR1/2 receptor antagonist PD-0220245 
Antiviral Efavirenz 
MDM2 inhibitor HLI-373989 
Bruton’s tyrosine kinase inhibitor Ibrutinib 
Retinoid, RAR-gamma agonist CD437 
DNMT inhibitor 5-azacytidine^ 
Non steroidal LXR agonist GW 3965 hydrochloride 
Topoisomerase II inhibitor Topotecan hydrochloride^ 
Arteminisin analogue NCGC00263270-01 


















Table 12. JHU-1016B Specific Hits 
 
Drug Mechanism of Action Drug Name 
VEGFR inhibitors Foretinib, Cedirinib, Sorafenib^, Regorafenib^ 
mTOR or PI3K or dual 
mTOR/PI3K inhibitors 
GDC-0980, Torin-2, PF-0521384,GSK-2126458, GDC-0941, 
Cdk/Chk inhibitor AT7519, Selicicib, PF-477736 
Hsp90/Hsp70 inhibitor Alvespimycin hydrochloride, VER-155008 
Proteasome Inhibitors Bortezomib, Carfilzomib 
TRPV4 antagonist DE-096 
c-MET inhibitor AMG-51, Crizotinib^ 
HDAC Inhbitors Romidepsin, AR-42 
Raf kinase inhibitor RAF-265 
USP2 inhibitor NCGC00262398-01 
Vitamin analogue 1-alpha-Hydroxyergocalciferol 
Jak2 inhibitor NVP-BSK805 
GR agonist Deactyl Cortivazol 
CAR agonist CITCO 
CFTR Channel Activator Ivacaftor^ 
Lck Inhibitor AMG-47a 
DNA-PK Inhibitor Ku0060648 
Plk inhibitor GSK-461364A 
Trk inhibitor AZ 23 
Aurora kinase inhibitor ENMD-981693 
EGFR inhibitor Gefitinib^ 
Monopolar spindle 1 inhibitor AZ-3146 
Wnt signaling Inhibitor ICG-001 
Tie2 inhibitor AMG-Tie2-1 









Hits were validated in additional oncosphere cell lines and tested in vivo 
Three compounds were chosen from the list of compounds that were cytotoxic in 
both JHH-136 and JHU-1016B cells for further validation in six additional oncosphere 
cell lines.  BIIB021, Bardoxolone methyl, and Obatoclax are all compounds that had 
similar IC50 values for both cell lines. BIIB021 and Bardoxolone methyl were effective in 
all cell lines tested at sub-micromolar concentrations and all dose response curves 
contained two asymptotes, as in the primary screen (Figure 10A-D). Obatoclax showed 
dissimilar IC50 values and dose response curves in all cell lines tested (Figure 10E-F). 
BIIB021 and Bardoxolone methyl were chosen for testing in vivo as single agents.  
Obatoclax was not tested due to a previous study showing a lack of single agent efficacy 
in an intracranial model of GBM (Cruickshanks et al.).  Br23C cells were implanted 
intracranially and treatment was started seven days following implantation.  BIIB021 
(75mg/kg) and Bardoxolone methyl (25mg/kg) were administered once daily by oral 
gavage Monday through Friday.  Control animals received vehicle by oral gavage.  
BIIB021 was well tolerated however it failed to increase MST (Figure 11A).  Animals 
treated with Bardoxolone methyl experienced significant weight loss so treatment was 
stopped for a period of three days then restarted at a lower dose (15mg/kg). This 
treatment group had a lower MST than control animals due to toxicity (Figure 11B).  
Taken together, this data shows that the qHTS format was successful in determining 
effective in vitro compounds, however this data did not translate into in vivo extension of 





Figure 10. Hit validation and secondary screening 
A. Dose response curves for BIIB021 from the primary screen using a qHTS format.   
B. Dose response curves for BIIB021 in six oncosphere cell lines using non-qHTS 
format 
C. Dose response curves for Bardoxolone methyl from the primary screen using a 
qHTS format.   
D. Dose response curves for Bardoxolone methyl in six oncosphere cell lines using a 
qHTS format.   
E. Dose response curves for Obatoclax from the primary screen using a qHTS format.  







Figure 11 - BIIB021 and Bardoxolone methyl show no single agent efficacy in vivo 
A. Kaplan Meier curve of the Br23C model treated with control or 75mg/kg of 
BIIB021.   
B. Kaplan Meier curve of the Br23C model treated with control or 25mg/kg of 





Drug Combination Matrix 
 Due to the lack of success with single agents from the MIPE screen in our glioma 
models, we sought to determine if drug combinations would be a better strategy.  We 
attempted to test Temozolomide in combination with compounds from the NINDS and 
Sigma-LOPAC drug libraries using a non-high throughput system in oncosphere cell 
lines.  Temozolomide and drug library compounds were kept at fixed concentrations of 
2μM and 4μM, respectively.  Hits selected from this assay were then validated using a 
range of concentrations for both drugs to obtain the synergistic range.  Issues encountered 
in this model were non-reproducibility of data and the short half-life of TMZ in vitro 
(Denny et al.).  Additionally, the use of fixed concentrations of both drugs in screening 
resulted in elimination of possible synergistic combinations. Clearly, a better system for 
screening would allow for testing multiple concentrations of two drugs simultaneously to 
assess synergy. 
 A high throughput drug combination matrix screening system was developed to 
allow for screening of many compounds using a range of concentrations.  First, we 
selected hits from our MIPE screen to be used in the drug combination matrix screen 
(Table 13).  These 29 compounds were combined in an all versus all matrix, using 6 
concentrations of both drugs.  JHH-136 was used for the 6x6 matrix screen.  435 drug 
combinations were done with 29 compounds.  Of these, 43 were chosen for an expanded 
10x10 matrix using 10 concentrations of both drugs (Table 14).  The 10x10 screen was 
done using JHH-136 and JHH-520.  The data from these screens revealed interesting 




Table 13. Compound list of drugs used in the 6x6 all versus all matrix and the IC50 values 











Table 14. Drug combinations selected for 10x10 matrix 
Drug Combinations 
Carfilzomib + Bardoxolone methyl GSK-2126458 + Bardoxolone methyl Trametinib + AZD-8055 
Carfilzomib + Cladribine GSK-2126458 + CNF-2024 Trametinib + CNF-2024 
Carfilzomib + GSK-2126458 GSK-2126458 + Marizomib Trametinib + Marizomib 
Carfilzomib + PAC-1 GSK-2126458 + Navitoclax Trametinib + Navitoclax 
Carfilzomib + SR-3306 GSK-2126458 + PAC-1 Trametinib + PAC-1 
Cladribine + AZD-8055 GSK-2126458 + Trametinib Trametinib + Pelitinib 
Cladribine + CNF-2024 Mebendazole + AZD-8055 Trametinib + SR-3306 
Cladribine + GSK-2126458 Mebendazole + OSI-027  
Cladribine + Marizomib Mebendazole + Navitoclax  
Cladribine + Mebendazole Mebendazole + Pelitinib Self Crosses: 
Cladribine + Navitoclax Obatoclax + AZD-8055 Cladribine 
Cladibrine + Obatoclax Obatoclax + CNF-2024 GSK-2126458 
Cladribine + PAC-1 Obatoclax + GDC-0941 Mebendazole 
Cladribine + Pelitinib Obatoclax + Mebendazole Obatoclax 
Cladribine + Trametinib Obatoclax + Pelitinib Trametinib 
GDC-0941 + CNF-2024 PAC-1 + CNF-2024  

















PI3K Inhibitors are synergistic in many drug combinations 
GSK-2126458 is dual PI3K/mTOR inhibitor that has shown efficacy in animal 
models of breast cancer (Knight et al.).  As a single agent, this compound had similar 
efficacy in JHH-136 and JHH-520 with a maximum response rate of approximately 40%.  
This compound showed synergy in combination with many compounds in the 10x10 
screen for both JHH-136 and JHH-520.  The most synergistic combinations were GSK-
2126458 paired with either Marizomib or Trametinib (Figure 12).  Marizomib, a 
proteasome inhibitor, is a very effective single agent drug in JHH-136 and JHH-520, 
killing 100% of cells. Combining Marizomib with GSK-2126458 lowered the 
concentration of Marizomib needed to kill 100% of cells. Carfilzomib, another 
proteasome inhibitor, had a similar downshift in the concentration needed to kill 100% of 
cells when combined with GSK-2126458.  Trametinib, a MEK inhibitor, has similar 
efficacy to GSK-2126458 as a single agent yet the combination treatment causes 100% 
cell death. GSK-2126458 was also combined with CNF-2024, Navitoclax, PAC-1, and 
Bardoxolone methyl but little to no synergy was observed in these combinations.  Overall, 
more synergy in these combinations were present in JHH-136 than JHH-520, however 

















Figure 12. Most synergistic GSK-2126458 combinations. 
Graph of inhibition in JHH-136 or JHH-520 cell treated with single agents or drug 







Trametinib and Cladribine drug combinations are more effective in JHH-136 
 Trametinib, an FDA approved MEK inhibitor, was also synergistic with many 
compounds (Figure 13).  GSK-2126458, as discussed previously, was one of the most 
effective Trametinib combinations.  AZD-8055, SR-3306 and Navitoclax were also very 
synergistic when combined with Trametinib in JHH-136.  The synergy was not as defined 
for these same drug combinations in JHH-520.  AZD-8055 is an mTOR inhibitor with a 
maximum response rate of approximately 60% as a single agent.  In combination with 
Trametinib, 100% of cell death occurs at the highest concentrations in JHH-136.  This 
combination was less efficacious in JHH-520.  SR-3306, a JNK inhibitor, has similar 
single agent efficacy to Trametinib, but the combination of both drugs causes 100% cell 
death in JHH-136.  In JHH-520, there is no difference in cell death in SR-3306 and 
Trametinib plus SR-3306.  Another drug that was synergistic in combination with 
Trametinib was Navitoclax, a Bcl-xL and Bcl2 inhibitor.  This drug combination was 
interesting due to the minimal activity of Navitoclax as a single agent in JHH-136 and 
JHH-520.  Navitoclax in combination with Trametinib causes 100% cell death in JHH-
136 but in JHH-520 the synergy is only present at the highest concentrations. Trametinib 
was also combined with CNF-2024, Pelitinib, and PAC-1.  These combinations caused 
30% or less viable cells but the efficacy was similar to single agent efficacy of one drug 
within the combination.   
 There was one compound with vastly different single agent activity in one of the 
two cell lines used for screening.  Cladribine, an FDA approved adenosine deaminase 
inhibitor, causes cell death by damaging DNA.  As a single agent, Cladribine has a 
maximum response rate of less than 10% in JHH-136. However in JHH-520, Cladribine 
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has a maximum response rate of 80%.  Cladribine was combined with 11 drugs and the 
most effective combinations in JHH-136 were with GSK-2126458 and Pelitinib.  Both 
these combinations caused lower concentrations of Cladribine to be more efficacious 
(Figure 14).  For JHH-520, both combinations produce the same result as GSK-2126458 
or Pelitinib as single agent.  This data is consistent with the single agent drug screen 
which found that Cladribine was ineffective in JHU-1016B yet very efficacious in JHH-
136. Other drug combinations in JHH-136 involving Cladribine caused minimal benefit 







Figure 13 (below). Combinations with Trametinib are synergistic. 













 JHH-136   JHH-520 
 
 JHH-136   JHH-520 
 
















Figure 14. Cladribine combinations are only synergistic in JHH-136. 








Drug combinations involving compounds with single agent efficacy in vivo had 
minimal synergy 
Drugs were also tested that our lab has evidence of single agent efficacy in GBM 
animal models.  Mebendazole is an anti-helmenthic drug that was found to extend 
survival in mouse and rat models of glioma (Bai et al.).  Mebendazole acts as a 
microtubule polymerization inhibitor, which has various anti-cancer mechanisms 
including the induction of apoptosis.  In vitro, the IC50 of Mebendazole is higher in 
glioma stem cells than in adherent cell lines and the maximum response rate is 90% or 
greater in JHH-136 and JHH-520.  Mebendazole was combined with Cladribine, Pelitinib, 
GDC-0941, Navitoclax, Obatoclax, AZD-8055, and OSI-027. Of these Navitoclax was 
the most synergistic in both cell lines, however this combination had a maximum 
response rate of 25-50% (Figure 15).  As mentioned previously, Navitoclax as a single 
agent has minimal drug efficacy.  All other combinations with Mebendazole, such as 
GDC-0941, had minimal difference in efficacy between the combination and the single 
agent.  Mebendazole intracranial concentrations can reach 3 μM so this drug combination 
will require further exploration. 
 PAC-1 is a caspase 3 activator that extends survival in mouse and rat models of 
GBM.  Caspase 3 levels are high in our oncosphere cell lines which correlates well with 
drug efficacy (Peterson et al.).  As a single agent, PAC-1 had minimal activity in JHH-
136 and JHH-520.  PAC-1 was combined with Carfilzomib, SR-3306, GSK-2126458, 
Cladribine, CNF-2024 and Trametinib.  The most synergistic of these combinations was 
Carfilzomib with PAC-1 in JHH-136 (Figure 15).  This combination lowered the 
concentration of Carfilzomib needed to cause 100% cell death.  This level of synergy was 
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not present in JHH-520.  Other combinations with PAC-1, such as PAC-1 and GSK-
2126458, failed to show even minimal synergy in either cell line.  Further studies must be 







Figure 15 (below). Mebendazole and PAC-1 combinations were not synergistic 
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GDC-0941 paired with CNF-2024, PD0325901 or Marizomib extend survival in vivo  
We wanted to determine whether the in vitro data could be replicated in vivo.  The 
JHH-520 cell line was an excellent candidate for in vivo experimentation.  This cell line 
was used in the 10x10 matrix experiments and has a MST of 82 days when implanted 
intracranially in nude mice.  The xenograft tumors produced by JHH-520 are very 
invasive with areas of necrosis and mitotic figures.  Next, we selected three drug 
combinations for testing in vivo. 
Overall, GSK-2126458 was the only compound that could be combined 
synergistically with multiple drugs in either cell line therefore we chose to have a PIK3 
inhibitor present in all combinations tested.  GDC-0941 is a PIK3 inhibitor that was used 
in the drug combination matrix screen.  Structurally, GDC-0941 and GSK-2126458 are 
dissimilar however they have a common target of the p110 subunit of PIK3.  The largest 
difference between the two drugs is that GDC-0941 has some inhibition of mTOR but 
GSK-2126458 is a more potent mTOR inhibitor.  GDC-0941 does penetrate the BBB, 
however the upper limit of how much drug gets into the brain is unknown (Salphati et al.).  
GDC-0941 was chosen to substitute for GSK-2126458.   
Trametinib was a drug that was successful in combination with GDC-0941, 
however Trametinib has minimal BBB penetration (Gilmartin et al.).  PD0325901  is a 
MEK inhibitor that is able to penetrate the BBB and has already been tested as a single 
agent in an intracranial GBM model (See et al.).  CNF-2024 is an Hsp90 inhibitor with 
the ability to penetrate the BBB (confidential source) so this drug was selected for use in 
animal studies.  Marizomib had evidence of brain penetration when given by intravenous 
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administration so this drug was consistent from the matrix screen to the in vivo testing 
(Williamson et al.), 
 The three combinations chosen were GDC-0941 paired with CNF-2024, 
PD0325901 or Marizomib.  One control group was used for all three experiments. The 
GDC-0941 plus CNF-2024 treated group had a MST of 85 days compared to the 
untreated control group MST of 69 days (Figure 16).  The MST of GDC-0941 plus 
Trametinib is 99.5 days, which is a significant improvement over the control group 
(Figure 16).  The MST of GDC-0941 plus Marizomib is 104 days.  Although the p value 
for this group was not significant, this was due to a single early mouse death.  
Additionally, this group had 2 of 5 animals live until termination of the experiment at 130 
days with no outward signs of tumor.  This data is excellent evidence that PIK3 inhibitors 






Figure 16 (below). Drug combinations in vivo with GDC-0941 extend survival in JHH-
520 model 
Kaplan Meier curves for the JHH-520 model treated with control (vehicle) or GDC-0941 





























Summary of Results 
 The purpose of this study was to develop a genomically characterized GBM 
oncosphere panel for in vitro and in vivo drug screening and development.   We 
developed nine GBM oncosphere cell lines from patient derived tumors then determined 
the full genomic profile of each cell line.  The genomic profile will be important to better 
interpret future research performed with these cell lines.   
Next, we subjected two of these cell lines to a quantitative high throughput drug 
screen using a drug library composed of drugs proven to be effective in a variety of 
cancers.  This study also provides additional evidence that oncospheres are amenable to a 
high throughput format, in addition to previous studies (Hothi et al.).  We validated the 
hits in a non-high throughput format in additional oncosphere cell lines and found that 
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drug response differed depending on the cell line, perhaps due to the different driver 
mutation profiles. This data supports previous observations that cell line characteristics 
alter drug efficacy and underscore that genomic data should be used to inform future drug 
studies and clinical trials.  
  In vivo testing of CNF-2024 and Bardoxolone methyl failed to extend survival in 
the Br23C model.  This data is evidence that single agent efficacy in vitro is difficult to 
replicate in vivo due to issues of toxicity, therapeutic window and brain penetration of the 
drug.  Finally, we completed further drug combination screening using a novel qHTS 
matrix format.  We found that PI3K inhibitors were synergistic with a variety of 
compounds in both cell lines tested. We selected compounds for animal testing by 
researching the ability of the compound to penetrate the BBB.  Animal studies revealed 
that GDC-0941 in combination with three different drugs was able to extend survival in 
the JHH-520 model. This data is shows that careful consideration must be taken to assess 
the PK/PD properties of drugs prior to therapeutic testing.  Overall, this project shows 
that our oncosphere cell lines are suitable for use in vitro and in vivo for therapeutic 
testing. 
Each Oncosphere Cell Line is a Unique, Independent GBM Model 
Genetic alterations common in primary GBM tissue has been widely studied and 
genes that likely drive GBM formation and growth have been determined (Parsons et al.; 
McLendon et al.). We found that our GBM oncosphere cell lines have alterations in GBM 
driver genes at similar frequencies to studies using primary tissue.  The most common 
alterations we found were loss of CDKN2A and PTEN, the latter resulting in uncontrolled 
cell growth and overactive signaling through the PI3K/AKT pathway.  Only two of our 
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cell lines contained EGFR amplification, which is a lower frequency than reported in 
primary tumor samples, suggesting a selection bias.  It has been well documented that 
EGFR amplification and alterations are difficult to maintain in cell culture (Chen et al.). 
Many of our cell lines contained NF1 alterations which causes overactive signaling 
through the Ras/MAPK pathway.  This could be due to selective pressure for maintaining 
mutations that are advantageous for growth in culture.  When protein expression was 
verified by western blot, we found a few inconsistencies to the sequencing data.  These 
could be explained by epigenetic silencing mechanisms, mutations not considered in 
regulatory regions or other unforeseen mutational affects resulting in a loss of protein 
expression. 
 Previous studies show that GBM oncospheres grown in serum free conditions 
better maintain the parent tumor genomic mutation profile, than adherent cell lines grown 
with serum.  Additionally, our GBM oncosphere cell lines can form intracranial tumors, 
which contain features of human GBM such as invasive growth and areas of necrosis.  
The use of U87MG, U251 and other adherent GBM cell lines lack the ability to form 
tumors in vivo that resemble human GBM which makes them a poor model for pre-
clinical studies used to inform clinical trials. We hope that through widespread use of our 
GBM oncosphere panel, there can be pre-clinical studies done to inform successful 
clinical trials to improve treatment options for GBM patients. 
Drug Efficacy can be dictated by the Characteristics of the Model Tested 
Our qHTS study revealed a number of different drug classes that were effective at 
stopping GBM cell growth.  We utilized two oncosphere cell lines with two different 
mutation profiles and found that EGFR inhibitors, NF-κB inhibitors, apoptosis activators 
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and epigenetic modulators were effective in both cell lines tested.  When examining hits 
that were effective in JHH-136, a PTEN null and NF1 wild type cell line, EGFR 
inhibitors were the only dominant drug class.   For JHU-1016B, a PTEN mutant and NF1 
null cell line, dominating drug classes were VEGFR, mTOR, PI3K inhibitors and 
Cdk/Chk inhibitors.  This difference in the type and amount of effective inhibitors was 
unexpected.  This study shows that genomic alterations in GBM driver genes can greatly 
affect drug efficacy.   
The drug combination studies revealed similar results as the single agent studies.  
Most drugs selected for use in the combination matrix screen were effective in both JHH-
136 and JHU-1016B, however when drug combinations were tested in JHH-520, there 
were differences in synergy. We believe this is due to the differences in the genomic 
mutation profile of JHH-136 and JHH-520.  The drug combinations involving GSK-
2126458, a PIK3 inhibitor, were the only combinations that showed maximal inhibition 
through synergy rather than extreme efficacy of a single agent within the combination.  
Other drug combinations involving highly efficacious single agents had maximal 
inhibition but synergy was minimal.  This result was unexpected.  This distinction is 
critical for future studies with drug combinations in humans. 
The animal studies using single agents were unsuccessful.  The common result is 
further evidence that in vitro efficacy does not always translate to in vivo efficacy.  There 
are a number of reasons why in vivo efficacy is difficult to predict.  This could be due to 
the differences in the models used for screening compared to in vivo testing.  Also, our 
use of intracranial GBM models adds an additional hurdle of the drugs ability to cross the 
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BBB. CNF-2024 has published data showing that it is able to cross the BBB while 
Bardoxolone methyl has no findings published in this area.  
Another interesting finding from the drug combination studies was which types of 
drugs could be paired together to produce maximal inhibition.  GDC-0941 has been 
shown to cross the BBB (Salphati et al.) and has been tested in other cancers (Sos et al.; 
Hoeflich et al.)  (Munugalavadla et al.), including glioma (Raynaud et al.).  This 
compound is currently in multiple clinical trials for solid tumors. CNF-2024 or BIIB021 
is a novel Hsp90 inhibitor with some ability to cross the BBB and recently completed 
Phase I clinical trials (Saif et al.). PD325901 has been tested as a single agent in an 
intracranial GBM model and showed a survival benefit (See et al.).  Marizomib is a 
compound produced by a marine bacteria, Salinispora tropica, and is currently in Phase 
I/II clinical trials.  Marizomib’s ability to cross the BBB is somewhat controversial 
(Williamson et al.; Singh et al.).   The significant survival benefit seen in all three of the 
combinations tested was surprising however, in hindsight our selection of compounds 
with evidence of crossing the BBB must have played a major role.  Additionally, we used 
the same model in vitro and in vivo, which could also explain the success of all three 
combinations.  Further experiments must be done to determine if the survival extension is 
due to drug synergy or single agent efficacy. 
Future Directions 
 A large number of pre-clinical studies can be generated from this work.  Various 
EGFR inhibitors have been tested in clinical trials as single agents and in combination 
with other drugs however, they have yet to show improvement of GBM patient survival.  
NF-κB inhibitors and apoptotic activators have not been widely tested on GBM.  Further 
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studies should be done to test these classes of drug in GBM models in vivo.  This data can 
also be used to inform studies regarding drug combinations that will be successful in the 
clinic.   
The successful drug combinations we tested must be further explored to 
determine if the survival benefit is due to single agent efficacy or drug combination 
synergy.  Once this has been determined we will attempt to move forward with clinical 
trials for GBM patients using the successful drug or drug combinations.   
Summary 
Our study is evidence that our glioma oncosphere cell line panel is a suitable 
model for in vitro and in vivo testing of GBM therapeutics. Our study also highlights the 
importance of the mutation profile of each individual patient tumor and how this can 
predict drug efficacy.  We hope that this study will lead to improved drug combinations 
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